Core Viewpoint - The article discusses the strategic market operations of Haixi New Drug (02637) over the past two months, highlighting a well-planned effort to increase market capitalization and liquidity in preparation for inclusion in the Hong Kong Stock Connect program [1][3]. Group 1: Market Operation Phases - The market operation can be divided into four distinct phases aimed at enhancing and stabilizing market capitalization to meet the Hong Kong Stock Connect inclusion criteria [3]. Phase 1: Accumulation - From October 20 to October 30, the stock price rose from 97.50, increasing by 18.63% over eight trading days, with a significant trading volume of 379.17 million and a turnover rate of 4.82% [4][5]. - The bullish trading volume accounted for 87.5%, indicating strong buying power and establishing a solid foundation for future operations [4]. Phase 2: Technical Adjustment - From October 31 to November 5, the stock experienced a technical adjustment with a price decline of 5.79% and a drastic drop in trading volume to 47.87 million, reflecting a controlled "volume reduction" strategy to clear short-term floating positions [5][6]. Phase 3: Breakthrough - From November 6 to November 12, the stock surged from 112.50 to 147.00, marking a 26.49% increase with a low turnover rate of 0.79%, indicating a high level of control by the main operators [7][8]. Phase 4: Consolidation - From November 13 to December 9, the stock price stabilized around 130.54, showing strong support with more bullish days than bearish ones, preparing for further market consensus and potential value expansion [9][10]. Group 2: Market Capitalization Strategy - Haixi New Drug has submitted an application for "full circulation" of shares, which will allow major shareholders to trade their shares in the secondary market after a 12-month lock-up period, enhancing the motivation for active market capitalization management [12]. - The company aims to exceed the core requirement of a daily average market capitalization of 93 billion HKD to qualify for the Hong Kong Stock Connect, achieving a market cap of 97.7 billion HKD as of December 10 [12][13]. - The strategy is designed to secure a "market capitalization safety cushion" by significantly increasing the market cap early in the assessment period, thus reducing the risk of falling below the required threshold [12][13].
冲刺港股通终检窗口：海西新药的“市值安全垫”与盘面语言